8-K: OrthoPediatrics Achieves Record 2025 Revenue, Issues Strong 2026 Guidance

OrthoPediatrics Corp. announced record preliminary unaudited full year 2025 revenue of $236.1 million and issued 2026 financial guidance projecting $262-$266 million in revenue and $25 million Adjusted EBITDA.

Summary

• Helped over 37,500 children in the fourth quarter 2025, contributing to nearly 1.3 million children helped since inception.
• Generated record preliminary unaudited full year 2025 net revenue of $236.1 million, representing 15% growth over $204.7 million in 2024.
• Preliminary full year domestic net revenue is expected to be $186.2 million, a 16% annual growth, and international net revenue is expected to be $49.9 million, a 15% annual growth.
• Generated preliminary unaudited fourth quarter 2025 net revenue of $61.3 million, representing 16% growth compared to $52.7 million in the fourth quarter of 2024.
• Preliminary domestic fourth quarter net revenue is expected to be $48.4 million (13% growth) and international net revenue is expected to be $12.9 million (32% growth).
• Generated approximately $6.0 $7.0 million in fourth quarter 2025 free cash flow, resulting in total year 2025 free cash flow usage being over 50% lower than total year 2024.
• Received EUMDR certification for Response Spine 4.5/5.0 and 5.5/6.0, as well as trauma and deformity plates, screws, intramedullary nails, and related instruments.
• Projects 2026 revenue to be in the range of $262 million to $266 million, representing 11% to 13% growth compared to full year 2025 preliminary unaudited net revenue.
• Expects approximately $10 million in annual set deployment and anticipates generating approximately $25 million Adjusted EBITDA in 2026.

Sentiment

Score: 9

Explanation: The filing reports record revenue, strong growth across all segments, significant improvement in free cash flow, and positive guidance for 2026, indicating very strong operational and financial performance.

Positives

• Achieved record preliminary unaudited full year 2025 net revenue of $236.1 million, representing 15% growth over the prior year.
• Demonstrated strong domestic net revenue growth of 16% and international net revenue growth of 15% for full year 2025.
• Reported significant international net revenue growth of 32% in Q4 2025.
• Generated $6.0 $7.0 million in free cash flow during Q4 2025, leading to over 50% lower total year 2025 free cash flow usage compared to 2024.
• Received EUMDR certification for key spine, trauma, and deformity products, enhancing market access and regulatory compliance.
• Issued positive 2026 financial guidance, projecting continued strong revenue growth (11% to 13%) and initiating guidance for record Adjusted EBITDA of approximately $25 million.
• The company has helped nearly 1.3 million children since its inception, highlighting its positive societal impact.

Risks

• The impact of widespread health emergencies, such as COVID-19 and respiratory syncytial virus, could materially affect results.
• Preliminary unaudited net revenue estimates for 2025 are subject to the completion of review and audit procedures by the independent registered public accounting firm and are therefore subject to adjustment.
• Actual fourth quarter and full year 2025 results could differ materially from the preliminary estimates provided.
• Net revenue for the full year ended December 31, 2026, could also differ materially from the forecasted amounts.
• Other known and unknown risks, uncertainties, and factors are set forth under 'Risk Factors' in the Annual Report on Form 10-K filed with the SEC on March 5, 2025, as updated and supplemented by other SEC reports.

Future Outlook

OrthoPediatrics projects 2026 revenue to be in the range of $262 million to $266 million, representing 11% to 13% growth over 2025. The company also expects approximately $10 million in annual set deployment and anticipates generating approximately $25 million in Adjusted EBITDA in 2026. Management is confident that growth drivers and operational discipline position the company to execute on its long-term outlook and continue making a meaningful impact for children worldwide.

Management Comments

• "Throughout 2025, we delivered another year of strong performance, advanced our strategic initiatives, and widened our leadership position in pediatric orthopedics."
• "Our Trauma and Deformity and Scoliosis implant businesses continued to execute effectively, taking market share, driving topline revenue, and improving profitability."
• "We are also extremely pleased with the specialty bracing (OPSB) business, which remains a tremendous market opportunity and a strategic catalyst for deepening customer relationships."
• "OPSB is proving to be a capital-efficient driver of both revenue and earnings, and we are only beginning to unlock its full potential as we scale in the years ahead."
• "Looking forward, we are confident that our growth drivers and operational discipline position us to execute on our long-term outlook and continue making a meaningful impact for children worldwide."

Industry Context

OrthoPediatrics operates exclusively in the specialized pediatric orthopedics market. The company's reported market share gains in its Trauma and Deformity and Scoliosis implant businesses, coupled with the strong performance and strategic potential of its specialty bracing (OPSB) business, indicate robust execution within its niche. The achievement of EUMDR certification for key products is a significant step, demonstrating compliance with evolving European regulatory standards and expanding product reach in international markets, which is crucial for growth in the global medical device industry.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, record revenue, reduced cash usage, and positive future guidance, potentially leading to increased share value.
• Customers (Children with orthopedic conditions): Positive impact as the company continues to help a growing number of children (nearly 1.3 million since inception) with its comprehensive product offerings.
• Employees: Positive outlook due to company growth and market leadership, suggesting stability and potential for expansion.
• Regulatory Authorities: Compliance demonstrated by EUMDR certification for key products.

Next Steps

• Release fourth quarter and full year 2025 financial results and provide additional commentary on financial outlook in late February to early March 2026.
• Complete review and audit procedures by the independent registered public accounting firm for 2025 financial estimates.
• Continue to scale the specialty bracing (OPSB) business in the years ahead to unlock its full potential.

Key Dates

Recommendation

The company has demonstrated exceptional financial performance with record revenue growth, significant improvement in free cash flow, and strong guidance for 2026, including projected record Adjusted EBITDA. Its strategic initiatives, such as the specialty bracing business and EUMDR certifications, position it for continued market share gains and sustained growth in the specialized pediatric orthopedics market. These factors indicate robust operational execution and a positive outlook, making it an attractive investment.

Keywords

pediatric orthopedics, OrthoPediatrics, KIDS, revenue, financial guidance, EBITDA, free cash flow, EUMDR certification, medical devices, spine, trauma, deformity, scoliosis, specialty bracing